CAR T-Cell Therapy for ALL Axicabtagene ciloleucel (KTE-C19) is also being investigated in the ZUMA-3 and ZUMA-4 trials for treatment of relapsed/refractory acute lymphoblastic leukemia (r/r ALL) in adult and …
CAR-T Cell Therapy HCP Guide – KTE-C19 Studies – Zuma 3 & 4 Trials Read More
ZUMA-2 Trial: Mantle Cell Lymphoma In the ZUMA-2 trial, Kite Pharma is also evaluating the treatment of relapsed/refractory mantle cell lymphoma (MCL) with KTE-C19. MCL is an aggressive B-cell lymphoma …
CAR-T Cell Therapy HCP Guide – KTE-C19 Studies – Zuma 2 Trials Read More
Hematologic Cancers: On Deck for CAR T Emerging immunotherapies such as chimeric antigen receptor (CAR) T-cell therapies are some of the most exciting new investigational agents in oncology today. Clinical …
CAR-T Cell Therapy HCP Guide – KTE-C19 Studies – Zuma 1 Trials Read More
From the early clinical trials involving chimeric antigen receptor T cell therapy (CAR-T), cytokine release syndrome has been a major problem. To block the high levels of interleukin 6, what …
StatPearls Question of the Week – #3 Read More
April 21, 2017 (Medical News Today) André Veillette and a team of researchers at the Institut de recherches cliniques de Montréal (IRCM) / Montreal Clinical Research Institute have discovered why …
Why Does Immunotherapy Work in Some Patients but not in Others? Read More
January 19, 2017 (Discovery Medicine) Sarcomas are rare and aggressive malignancies of bone and soft tissue affecting all ages of patients that are usually incurable when non-responsive to chemotherapy and …
Advances in Treating Sarcoma with Immunotherapy Read More
CAR T-Cell Therapy: How It Works Chimeric antigen receptor (CAR) T-cell therapy is an investigational form of immunotherapy — in fact, the first gene therapy — if FDA-approved. CAR T …
CAR-T Cell Therapy HCP Guide – Mechanism of Action Read More
December 17, 2015 (Leukemia & Lymphoma Society) Dr. Steven Rosenberg explains why immunotherapies provides the best clues for cancer treatments for patients who can’t be helped by current drugs.
VIDEO: Dr. Steven Rosenberg on saving lives with Car T Therapy Read More What is the most common adverse effect of chimeric antigen receptor therapy (CAR-T)? A. Reactivation of tuberculosis B. Stevens-Johnson syndrome C. Cytokine release syndrome D. Neurotoxicity Click for the answer …
StatPearls Question of the Week #2 Read More
April 26, 2017 (Medical News Today) Cellular therapy hasn’t had much success in fighting solid tumors, partly because it’s been difficult to deliver anti-cancer T cells to the tumors. A …
Implanted scaffold with T cells rapidly shrinks tumors Read More